Description: Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Home Page: www.idorsia.com
Hegenheimermattweg 91
Allschwil,
4123
Switzerland
Phone:
41 58 844 10 10
Officers
| Name | Title |
|---|---|
| Mr. Jean-Paul Clozel M.D. | CEO & Exec. Director |
| Mr. André C. Muller | Exec. VP & CFO |
| Dr. Martine Clozel | Exec. VP & Chief Scientific Officer |
| Mr. Andrew C. Weiss | Sr. VP and Head of Investor Relations & Corp. Communications |
| Mr. Julien Gander L.L.M. | Sr. VP, Group Gen. Counsel & Company Sec. |
| Mr. Alexander Khatuntsev | Sr. VP & Head of Global HR |
| Dr. Guy Braunstein M.D. | Exec. VP & Chief Medical Officer |
| Mr. Simon Jose | Exec. VP & Chief Commercial Officer |
| Mr. Olivier Lambert | Sr. VP and Head of Global Pharmaceutical Devel. & Quality Assurance |
| Mr. Markus A. Riederer | Sr. VP & Head of Drug Discovery Biology |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 27.6461 |
| Price-to-Sales TTM: | 48.8403 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |